Neural Stem Cell Microparticles for Regenerative Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies face challenges such as the need for a consistent and substantial supply of functionally and phenotypically stable stem cells, high costs, time delays in cell generation, storage, transport, and handling, immunological compatibility issues, and regulatory concerns related to safety risks like tumor or ectopic tissue formation, as well as limited evidence for long-term effects of transplanted stem cells.
Innovation Solution
The development of neural stem cell microparticles, specifically exosomes, which are produced under controlled conditions in a multi-compartment bioreactor, allowing for large-scale production and improved stability, and can be used to enhance therapeutic efficacy by promoting tissue regeneration, angiogenesis, and neuroprotection, while reducing the risk of immune rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional stem cell therapy is used, then therapeutic efficacy is achieved, but there are high costs, time delays in cell generation and handling, and regulatory concerns
Solution Approach 1:
The invention extracts the therapeutic essence of stem cells by isolating and utilizing stem cell-derived extracellular vesicles (exosomes and microvesicles) that contain bioactive molecules. This extraction allows the therapeutic effects to be delivered without requiring live stem cells, thereby eliminating time delays associated with cell generation, expansion, and handling while maintaining therapeutic efficacy.
Solution Approach 2:
The invention creates a copy of the stem cell therapeutic effect through extracellular vesicles that carry bioactive molecules (proteins, lipids, nucleic acids) from stem cells. These vesicles serve as functional copies that can be produced, stored, and transported without the complexities of living cell culture, resolving the time delay and handling issues while preserving the core therapeutic mechanism.
2Reliability
If traditional stem cell therapy is used, then tissue repair is promoted, but there are immunological compatibility issues and risk of rejection
Solution Approach 1:
The invention extracts only the beneficial bioactive components (proteins, lipids, nucleic acids) from stem cells and delivers them through extracellular vesicles, while leaving behind the cellular components that trigger immune rejection. This separation allows tissue repair promotion without the harmful immunological effects of introducing live allogeneic or autologous stem cells.
3Reliability
If traditional stem cell therapy is used, then regenerative effects are achieved, but there are safety risks of tumour or ectopic tissue formation
Solution Approach 1:
The invention extracts and delivers only the differentiating and regenerative signals contained in stem cell-derived extracellular vesicles, while completely eliminating the stem cells themselves that possess the capacity for uncontrolled proliferation and tumour formation. This ensures regenerative effects are achieved without the safety risks of ectopic tissue formation or teratoma development.
4Quantity of substance
If large scale production of stem cells is attempted, then supply consistency is improved, but costs and complexity increase
Solution Approach 1:
The invention extracts the therapeutic payload from stem cells and delivers it through stable extracellular vesicles that can be produced in bioreactors without requiring complex cell culture infrastructure. This simplifies the production process, reduces costs, and improves supply consistency by eliminating the need for GMP-grade cell culture facilities, cryopreservation, and quality control of living cells.
Solution Approach 2:
The invention replaces expensive, complex, and fragile live stem cells with simpler, more stable extracellular vesicles that can be produced at lower cost and stored without specialized cryopreservation equipment. The vesicles are essentially disposable therapeutic products that can be manufactured, stored, and distributed through conventional pharmaceutical channels.
Data Source
Figure 1A~1F
Figure 2
Figure 3
AI summary
This invention relates to stem cell microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically an exosome or microvesicle and may be derived from a neural stem cell line. The neural stem cell line may be a conditionally-immortalised stem cell line such as CTX0E03 (deposited at the ECACC with Accession No. 04091601).